Ridge Preservation Using a Ossix™ Bone vs Bio-Oss® Collagen

TEETH EXTRACTION Clinical Trial

Official title:

Histological Evaluation of Healing Following Ridge Preservation Using a Composite Bovine Derived Xenograft or a Hydroxyapatite-Collagen Matrix

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04338516
• Other study ID #: HSC20190455H
• Status: Completed
• Phase: Phase 4
• Start date: November 1, 2019
• Est. completion date: March 10, 2022

Study information

• Verified date: April 2022
• Source: Datum Dental LTD
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized, parallel design, controlled study will assess the histologic healing of this Ossix™ Bone in humans and compare it to a Bio-Oss® Collagen that is well researched.

Subjects will be enrolled into 2 groups. Each subject will provide a single non-molar tooth site for study treatment. The tooth will be extracted, the extraction socket will be filled with one of the study bone grafts. No wound dressing or membrane will be used to cover the bone graft material as both materials can be used alone. An core biopsy will be collected after 16 weeks of healing during the implant placement.

The study will evaluate if there is a difference in histologic wound healing following tooth extraction and ridge preservation between groups treated with Bio-Oss® Collagen compared to Ossix™ Bone.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: March 10, 2022
• Est. primary completion date: December 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• One tooth, excluding molars, that has been identified by dental faculty as requiring a single tooth extraction

• A dental implant is indicated and treatment planned to replace the missing tooth

• Have adequate restorative space for a dental implant-retained restoration

• Have at least 10mm of alveolar bone height, without impinging on the maxillary sinus or inferior alveolar canal.

• Have a dehiscence of the buccal or lingual bony plate of the tooth socket extending no more than 50% of the total depth of the socket.

• Female patients who have undergone a hysterectomy, tubal ligation, or menopause, and non-pregnant women of child-bearing potential.

• Are nonsmokers or former smokers. Current smokers may be included if they smoke <10 cigarettes per day

Exclusion Criteria:

• Will not cooperate with the follow-up schedule. Patients will not be entered who are mentally incompetent, prisoners, or pregnant.

• Pregnant women or women intending to become pregnant during the study period (as confirmed verbally; an over the counter pregnancy test will be provided if pregnancy status is unknown or suspected).

• Patients who become pregnant during the study will be withdrawn and standard care will be delivered.

• Smokers who smoke >10 cigarettes per day

• Clinical and/or radiographic determinations which will preclude inclusion in this study are: Active infection other than periodontitis; Inadequate bone dimensions or restorative space for a dental implant; Presence of a disease entity, condition or therapeutic regimen which decreases probability of soft tissue and bony healing, e.g., poorly controlled diabetes, chemotherapeutic and immunosuppressive agents, autoimmune diseases, history of bisphosphonate use or long-term steroid therapy; Positive medical history of endocarditis following oral or dental surgery.

Related Conditions & MeSH terms

• TEETH EXTRACTION

Intervention

Device:
• Ossix™ Bone
a resorbable sponge-like matrix of 80% hydroxyapatite and 20% sugar cross-linked porcine collagen
• Bio-Oss® Collagen
90% bovine derived xenograft granules and 10% porcine collagen

Locations

Country	Name	City	State
United States	UT Health San Antonio (UTHSA)	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Datum Dental LTD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	percent vital bone formation,	shows the amount of new bone formed after the procedure	16 weeks
Primary	percent residual graft material	shows how much of the graft material remained intact	16 weeks
Primary	percent fibrous tissue and marrow space	amount of tissue that is neither native bone or graft material	16 weeks